[3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]decanoyl] 3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]dodecanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: [3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]decanoyl] 3-hydroxy-2-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]dodecanoate
• 化学式: C₃₄H₆₂O₁₃
• 分子量: 678.8
• InChiKey: YDQGKRGMBXPNII-PRJGIJJMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  47
• 可旋转键数：
  22
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  224
• 氢给体数：
  8
• 氢受体数：
  13

文献信息

• METHOD FOR TREATING DUPUYTREN'S DISEASE
  申请人：Dale Biotech, LLC

  公开号：US20220088047A1

  公开（公告）日：2022-03-24

  The present invention is directed to methods for treating Dupuytren's disease, osteoarthritis, and adhesive capsulitis. The method comprises the steps of identifying a subject in need thereof, and administering to the subject an effective amount of one or more rhamnolipids, optionally in combination with niclosamide. A pharmaceutical composition comprising rhamnolipids, optionally in combination with niclosamide or a salt thereof, can be applied by any accepted mode of administration including oral, topical, or injection within or around the affected body part such as an affected hand, knee, or shoulder.
• US8765694B2
  申请人：——

  公开号：US8765694B2

  公开（公告）日：2014-07-01
• US9107930B2
  申请人：——

  公开号：US9107930B2

  公开（公告）日：2015-08-18